We are international

Sydney 2005:
The International Staging System for Myeloma: An Update
By Philip Greipp, MD
Dr. Greipp provided an update on the International Staging System (ISS) for MM and indicated that an article on ISS is to be published in the May 20 issue of the Journal of Clinical Onoclogy. The staging system was developed after analyzing the data from 3 groups: Asia, Europe, and North America. The goal was to develop a validated and confirmed staging system for MM. Results from the study formed 3 stages based on ß2 microglobulin and albumin levels. A summary of survival outcomes based on these stages was presented: Stage 1 = 62 months, Stage 2 = 44 months, Stage 3 = 29 months. The ISS staging system may prove to be superior to the Durie Salmon staging system with more equal distribution across the 3 stages. Dr. Greipp suggested that the ISS system should be the only system used until another easily usable, validated, and confirmed system is developed.

Back to session summary

 related articles